Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01058655 · ClinicalTrials.gov registry record · Phase 1
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT01058655 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 56 participants.
The verdict
NCT01058655, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
Research has shown that anti-angiogenic agents can be effective therapies to treat cancer. Anti-angiogenic agents target the blood vessels required for tumors to grow. Vascular endothelial growth factor (VEGF) is one of the cell pathways used for this blood vessel growth. When the investigators interfere with the VEGF pathway, the investigators inhibit this blood vessel growth which is required by tumors. One of the study drugs being used, tivozanib (AV-951), selectively interferes with the VEGF pathway. The second study drug being used, everolimus (RAD001) interferes with the mTOR pathway. The mTOR pathway is another pathway involved in blood vessel and tumor cell growth. By combining these two drugs the investigators hope to slow or reverse tumor cell growth in patients whose tumors have become resistant to other therapies for their disease.
Interventions
- DRUG Everolimus
- DRUG Tivozanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2010-02 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01058655
The ClinicalTrials.gov registry entry for NCT01058655 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT01058655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01058655 about?
NCT01058655 is a clinical study titled "RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer". Research has shown that anti-angiogenic agents can be effective therapies to treat cancer. Anti-angiogenic agents target the blood vessels required for tumors to grow. Vascular endothelial growth factor (VEGF) is one of the cell pathways used for this blood vessel growth. When the investigators inte...
What is the current status of trial NCT01058655?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2010-02. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01058655?
The interventions under investigation include: Everolimus (DRUG), Tivozanib (DRUG).
Who is sponsoring clinical trial NCT01058655?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.